Currently, there are ongoing several clinical trials to evaluate the antitumor response as monotherapy in patients with advanced or metastatic endometrial cancer (NCT04205630) and in combination with niraparib in patients with HER-2 expressing advanced or metastatic endometrial, ovarian or breast tumors (NCT04235101). The gene discussed is ERBB2; the disease is endometrial cancer.